A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection
This is a study to evaluate the efficacy and safety of Bendamustine Hydrochloride Injection in subjects with Rituximab-resistant Indolent B-Cell Non-Hodgkin's Lymphomas.
Indolent B-Cell Non-Hodgkin's Lymphomas
DRUG: Bendamustine hydrochloride injection
Objective Response Rate（ORR）, Percentage of participants achieving complete response (CR) and partial response (PR)., Baseline up to 30 weeks|Duration of Response (DOR), DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment., Baseline up to 30 weeks
Progression Free Survival (PFS), PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause., Baseline up to 30 weeks|Overall Survival (OS), OS defined as the time from randomization to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., Baseline up to 30 weeks
This is a study to evaluate the efficacy and safety of Bendamustine Hydrochloride Injection in subjects with Rituximab-resistant Indolent B-Cell Non-Hodgkin's Lymphomas.